Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/164122
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSierra Ortigosa, Josep Maria-
dc.contributor.authorFusté i Domínguez, Ester-
dc.contributor.authorRabanal Anglada, Francesc-
dc.contributor.authorVinuesa Aumedes, Teresa-
dc.contributor.authorViñas, Miquel-
dc.date.accessioned2020-06-03T09:21:22Z-
dc.date.available2020-06-03T09:21:22Z-
dc.date.issued2017-04-11-
dc.identifier.issn1471-2598-
dc.identifier.urihttp://hdl.handle.net/2445/164122-
dc.description.abstractINTRODUCTION: The recent dramatic increase in the incidence of antimicrobial resistance has been recognized by organizations such as the United Nations and World Health Organization as well as the governments of the USA and several European countries. A relatively new weapon in the fight against severe infections caused by multi-drug resistant bacteria is antimicrobial peptides (AMPs). These include colistin, currently regarded as the last line of antimicrobial therapy against multi-drug resistant microorganisms. Areas covered: Here, the authors provide an overview of the current research on AMPs. The focus is AMPs currently being developed for the treatment of recalcitrant bacterial infections, the synergies of AMPs and antibiotics, and the activity of AMPs against biofilm. This review also includes a brief introduction into the use of AMPs in infections caused by Mycobacterium, fungi, and parasites. Expert opinion: In research into new antimicrobials, AMPs are gaining increasing attention. While many are natural and are produced by a wide variety of organisms, others are being newly designed and chemically synthesized in the laboratory to achieve novel antimicrobial agents. The same strategy to fight infections in nature is thus being effectively exploited to safeguard human and animal health.-
dc.format.extent14 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherTaylor and Francis-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1080/14712598.2017.1315402-
dc.relation.ispartofExpert Opinion On Biological Therapy, 2017, vol. 17, num. 6, p. 663-676-
dc.relation.urihttps://doi.org/10.1080/14712598.2017.1315402-
dc.rights(c) Taylor and Francis, 2017-
dc.sourceArticles publicats en revistes (Química Inorgànica i Orgànica)-
dc.subject.classificationAntibiòtics-
dc.subject.classificationPèptids-
dc.subject.classificationResistència als medicaments-
dc.subject.classificationEspectrometria de masses-
dc.subject.otherAntibiotics-
dc.subject.otherPeptides-
dc.subject.otherDrug resistance-
dc.subject.otherMass spectrometry-
dc.titleAn overview of antimicrobial peptides and the latest advances in their development-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec671790-
dc.date.updated2020-06-03T09:21:23Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Química Inorgànica i Orgànica)

Files in This Item:
File Description SizeFormat 
671790.pdf682.64 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.